https://www.selleckchem.com/pr....oducts/ly3214996.htm
BACKGROUND Clostridioides difficile infection is one of the most common health care-associated infections. To reduce the recurrent Clostridioides difficile infection (rCDI), monoclonal antibodies against Clostridioides difficile toxin A (actoxumab) and toxin B (bezlotoxumab) were developed. In the present study, we performed a systematic review and meta-analysis to assess their efficacy and safety. MATERIALS AND METHODS An electronic database was searched for relevant randomized controlled trials assessing bezlotoxumab and/or actoxuma
Like
Comment
Share
